Identification of large-scale characteristic genes of Mullerian inhibiting substance in human ovarian cancer cells

被引:7
|
作者
Nam, Suk Woo [2 ]
Jo, Yun Sung [1 ]
Eun, Jung Woo [2 ]
Song, Jae Yen [1 ]
Ryu, Ki Sung [1 ]
Lee, Jung Young [2 ]
Lee, Joon Mo [1 ]
MacLaughlin, David T. [3 ,4 ]
Kim, Jang Heub [1 ]
机构
[1] Catholic Univ Korea, Coll Med, Dept Obstet & Gynecol, Seoul 150713, South Korea
[2] Catholic Univ Korea, Microdissect Genom Res Inst, Dept Pathol, Seoul 150713, South Korea
[3] Massachusetts Gen Hosp, Pediat Surg Res Lab, Boston, MA 02114 USA
[4] Harvard Univ, Sch Med, Boston, MA 02114 USA
关键词
Mullerian inhibiting substance; OVCAR-8 cell line; DNA microarray; cell cycle; II RECEPTOR; HEPATOCELLULAR-CARCINOMA; INDEPENDENT MECHANISM; SEXUAL DEVELOPMENT; MOLECULAR-CHANGES; IN-VIVO; EXPRESSION; GROWTH; TARGET; DIFFERENTIATION;
D O I
10.3892/ijmm_00000168
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The purpose of this study was to investigate the large-scale characteristic molecular signature of Mullerian inhibiting substance (MIS) in human ovarian cancer cells through expression genomics. To understand the comprehensive molecular mechanisms by which MIS inhibits ovarian cancer cell growth, we identified the large-scale characteristic molecular changes elicited by MIS in the human ovarian cancer cell line OVCAR-8, using DNA microarray analysis. Combined serial gene expression analysis from 0 to 96 h after MIS treatment of OVCAR-8 cells resulted in 759 genes which showed at least a 2-fold change in overexpression or underexpression compared to non-treatment groups. Of the 759 outlier genes, 498 genes were mapped to known biological cellular processes, and the resultant major pathways included metabolism, signal transduction, cell growth and apoptosis. Among these pathways, 68 genetic elements were dissected as cell cycle-related genes induced by MIS. Although cellular phenotypic changes by MIS were observed after 24 h of treatment, the characteristic large-scale molecular changes were observed from 48 to 96 h of exposure to MIS. This finding may imply that the suppressive role of MIS on ovarian cancer cells could be cumulative in that the metabolic disturbance of MIS is followed by arrest at the G1/S cell cycle checkpoint. We suggest 759 outlier genes comprise the characteristic molecular signature of MIS, which may be responsible for the suppressive effect on OVCAR-8 cells. Although the precise biological mechanisms underlying these outlier genes should be validated, the genetic elements described herein provide promising therapeutic interventions for ovarian cancer.
引用
收藏
页码:589 / 596
页数:8
相关论文
共 50 条
  • [31] Functional identification of cancer-relevant genes through large-scale RNA interference screens in mammalian cells
    Brummelkamp, TR
    Berns, K
    Hijmans, EM
    Mullenders, J
    Fabius, A
    Heimerikx, M
    Velds, A
    Kerkhoven, RM
    Madiredjo, M
    Bernards, R
    Beijersbergen, RL
    COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, 2004, 69 : 439 - 445
  • [32] MULLERIAN INHIBITING SUBSTANCE INHIBITS COLONY GROWTH OF A HUMAN OVARIAN-CARCINOMA CELL-LINE
    FULLER, AF
    GUY, S
    BUDZIK, GP
    DONAHOE, PK
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1982, 54 (05): : 1051 - 1055
  • [33] Patterns of Mullerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer
    Basal, E.
    Ayeni, T.
    Zhang, Q.
    Langstraat, C.
    Donahoe, P. K.
    Pepin, D.
    Yin, X.
    Leof, E.
    Cliby, W.
    CURRENT MOLECULAR MEDICINE, 2016, 16 (03) : 222 - 231
  • [34] EFFECT OF HUMAN RECOMBINANT MULLERIAN INHIBITING SUBSTANCE ON ISOLATED EPITHELIAL AND MESENCHYMAL CELLS DURING MULLERIAN DUCT REGRESSION IN THE RAT
    TSUJI, M
    SHIMA, H
    YONEMURA, CY
    BRODY, J
    DONAHOE, PK
    CUNHA, GR
    ENDOCRINOLOGY, 1992, 131 (03) : 1481 - 1488
  • [35] Large-scale profiling of metabolic dysregulation in ovarian cancer
    Ke, Chaofu
    Hou, Yan
    Zhang, Haiyu
    Fan, Lijun
    Ge, Tingting
    Guo, Bing
    Zhang, Fan
    Yang, Kai
    Wang, Jingtao
    Lou, Ge
    Li, Kang
    INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (03) : 516 - 526
  • [36] Mullerian Inhibiting Substance Type 2 Receptor (MISIIR)-Specific CAR T Cells for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies
    Rodriguez-Garcia, Alba
    Sharma, Prannda
    Poussin, Mathilde
    Robinson, Matthew K.
    Gitto, Sarah B.
    Medvedev, Sergey
    Adams, Gregory P.
    Simpkins, Fiona
    Powell, Daniel J.
    MOLECULAR THERAPY, 2019, 27 (04) : 320 - 320
  • [37] Expression of Mullerian-Inhibiting Substance/Anti-Mullerian Hormone Type II Receptor in the Human Theca Cells
    Cheon, Keun Young
    Chung, Youn Jee
    Cho, Hyun Hee
    Kim, Mee Ran
    Cha, Jung Ho
    Kang, Chang Suk
    Lee, Jung Young
    Kim, Jang Heub
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2018, 103 (09): : 3376 - 3385
  • [38] Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer
    Hough, CD
    Sherman-Baust, CA
    Pizer, ES
    Montz, FJ
    Im, DD
    Rosenshein, NB
    Cho, KR
    Riggins, GJ
    Morin, PJ
    CANCER RESEARCH, 2000, 60 (22) : 6281 - 6287
  • [39] Identification of cancer genes and their collaborative networks by large-scale mutagenesis in tumour prone mice
    Berns, A.
    Uren, A.
    Kool, J.
    De Ridder, J.
    Mattison, J.
    Jonkers, J.
    Wessels, L.
    Adams, D.
    Van Lohuizen, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 81 - 81
  • [40] AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer
    Pepin, David
    Sosulski, Amanda
    Zhang, Lihua
    Wang, Dan
    Vathipadiekal, Vinod
    Hendren, Katherine
    Coletti, Caroline M.
    Yu, Aaron
    Castro, Cesar M.
    Birrer, Michael J.
    Gao, Guangping
    Donahoe, Patricia K.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (32) : E4418 - E4427